Preclinical and Clinical Experience with Fulvestrant (Faslodex) in Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer

References

• Margolese, R G.; Fisher, B.; Hortobagyi, G N.; Bloomer, W D. Neoplasms of the breast. In Cancer Medicine, 5th Ed.; Bast, R C., Kufe, D W., Pollock, R E., Weichselbaum, R R., Holland, J F., Frei, E., III, Eds.; BC Decker: Hamilton, 2000; 1735–1822.
   Google Scholar
• Anderson, W F.; Chatterjee, N.; Ershler, W B.; Brawley, O W. Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Res. Treat. 2002, 76 (1), 27–36. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Buzdar, A U.; Hortobagyi, G. Update on endocrine therapy for breast cancer. Clin. Cancer Res. 1998, 4 (3), 527–534. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ravdin, P M.; Green, S.; Dorr, T M.; McGuire, W L.; Fabian, C.; Pugh, R P.; Carter, R D.; Rivkin, S E.; Borst, J R.; Belt, R J. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J. Clin. Oncol. 1992, 10 (8), 1284–1291. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Yao, K.; Jordan, V C. Questions about tamoxifen and the future use of antiestrogens. Oncologist 1998, 3, 104–110. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998, 351 (9114), 1451–1467. [CROSSREF]
   PubMed Web of Science ®Google Scholar
• ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359 (9324), 2131–2139. [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Osborne, C K.; Coronado-Heinsohn, E B.; Hilsenbeck, S G.; McCue, B L.; Wakeling, A E.; McClelland, R A.; Manning, D L.; Nicholson, R I. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J. Natl. Cancer Inst. 1995, 87 (10), 746–750. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Delmas, P D.; Bjarnason, N H.; Mitlak, B H.; Ravoux, A C.; Shah, A S.; Huster, W J.; Draper, M.; Christiansen, C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 1997, 337 (23), 1641–1647. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Buzdar, A U.; Hortobagyi, G N. Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy. J. Clin. Oncol. 1998, 16 (1), 348–353. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Stenbygaard, L E.; Herrstedt, J.; Thomsen, J F.; Svendsen, K R.; Engelholm, S A.; Dombernowsky, P. Toremifene and tamoxifen in advanced breast cancer—a double-blind cross-over trial. Breast Cancer Res. Treat. 1993, 25 (1), 57–63. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lee, E S.; Schafer, J M.; Yao, K.; England, G.; O'Regan, R M.; De Los Reyes, A.; Jordan, V C. Cross resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice. Clin. Cancer Res. 2000, 6 (12), 4893–4899. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Vogel, C L.; Shemano, I.; Schoenfelder, J.; Gams, R A.; Green, M R. Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer. J. Clin. Oncol. 1993, 11 (2), 345–350. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Harvey, H A. Clinical use of aromatase inhibitors in breast carcinoma. In Cancer Medicine, 5th Ed.; Bast, R C., Kufe, D W., Pollock, R E., Weichselbaum, R R., Holland, J F., Frei, E., III., Eds.; BC Decker: Hamilton, 2000; 1735–1822.
   Google Scholar
• Bonneterre, J.; Buzdar, A.; Nabholtz, J M.; Robertson, J F.; Thürlimann, B.; von Euler, M.; Sahmoud, T.; Webster, A.; Steinberg, M. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001, 92 (9), 2247–2258. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Mouridsen, H.; Gershanovich, M.; Sun, Y.; Perez-Carrion, R.; Boni, C.; Monnier, A.; Apffelstaedt, J.; Smith, R.; Sleeboom, H P.; Janicke, F.; Pluzanska, A.; Dank, M.; Becquart, D.; Bapsy, P P.; Salminen, E.; Snyder, R.; Lassus, M.; Verbeek, J A.; Staffler, B.; Chaudri-Ross, H A.; Dugan, M. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J. Clin. Oncol. 2001, 19 (10), 2596–2606. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Paridaens, R.; Therasse, P.; Dirix, L.; Beex, L.; Piccart, M.; Cameron, D.; Cufer, T.; Roozendaal, K.; Nooij, M.; Mattiacci, M.-R. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts)-a randomized phase III trial of the EORTC Breast group. Proc. Am. Soc. Clin. Oncol. 2004, 23, 515. Abstract.
   Google Scholar
• Buzdar, A U.; Jonat, W.; Howell, A.; Jones, S E.; Blomqvist, C P.; Vogel, C L.; Eiermann, W.; Wolter, J M.; Steinberg, M.; Webster, A.; Lee, D. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 1998, 83 (6), 1142–1152., [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Dombernowsky, P.; Smith, I.; Falkson, G.; Leonard, R.; Panasci, L.; Bellmunt, J.; Bezwoda, W.; Gardin, G.; Gudgeon, A.; Morgan, M.; Fornasiero, A.; Hoffmann, W.; Michel, J.; Hatschek, T.; Tjabbes, T.; Chaudri, H A.; Hornberger, U.; Trunet, P F. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J. Clin. Oncol. 1998, 16 (2), 453–461. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Kaufmann, M.; Bajetta, E.; Dirix, L Y.; Fein, L E.; Jones, S E.; Zilembo, N.; Dugardyn, J L.; Nasurdi, C.; Mennel, R G.; Cervek, J.; Fowst, C.; Polli, A.; di Salle, E.; Arkhipov, A.; Piscitelli, G.; Miller, L L.; Massimini, G. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J. Clin. Oncol. 2000, 18 (7), 1399–1411. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Boccardo, F.; Rubagotti, A.; Amoroso, D.; Mesiti, M.; Romeo, D.; Caroti, C.; Farris, A.; Cruciani, G.; Villa, E.; Schieppati, G.; Mustacchi, G.; Italian Breast Cancer Cooperative Group. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study. J. Clin. Oncol. 2001, 19 (22), 4209–4215. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Wakeling, A E.; Bowler, J. Steroidal pure antioestrogens. J. Endocrinol. 1987, 112 (3), R7–R10. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Wakeling, A E.; Dukes, M.; Bowler, J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991, 51 (15), 3867–3873. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Borras, M.; Laios, I.; el Khissiin, A.; Seo, H S.; Lempereur, F.; Legros, N.; Leclercq, G. Estrogenic and antiestrogenic regulation of the half-life of covalently labeled estrogen receptor in MCF-7 breast cancer cells. J. Steroid Biochem. Mol. Biol. 1996, 57 (3–4), 203–213. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Pink, J J.; Jordan, V C. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res. 1996, 56 (10), 2321–2330. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Wakeling, A E. Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr.-Relat. Cancer 2000, 7 (1), 17–28. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Dukes, M.; Miller, D.; Wakeling, A E.; Waterton, J C. Antiuterotrophic effects of a pure antioestrogen, ICI 182,780: magnetic resonance imaging of the uterus in ovariectomized monkeys. J. Endocrinol. 1992, 135 (2), 239–247. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Osborne, C K.; Jarman, M.; McCague, R.; Coronado, E B.; Hilsenbeck, S G.; Wakeling, A E. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother. Pharmacol. 1994, 34 (2), 89–95. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• DeFriend, D J.; Howell, A.; Nicholson, R I.; Anderson, E.; Dowsett, M.; Mansel, R E.; Blamey, R W.; Bundred, N J.; Robertson, J F.; Saunders, C. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res. 1994, 54 (2), 408–414. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Robertson, J F.; Nicholson, R I.; Bundred, N J.; Anderson, E.; Rayter, Z.; Dowsett, M.; Fox, J N.; Gee, J M.; Webster, A.; Wakeling, A E.; Morris, C.; Dixon, M. Comparison of the short-term biological effects of 7alpha-[9–(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res. 2001, 61 (18), 6739–6746. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Bundred, N J.; Anderson, E.; Nicholson, R I.; Dowsett, M.; Dixon, M.; Robertson, J F. Fulvestrant, an estrogen receptor downregulator, reduces cell turnover index more effectively than tamoxifen. Anticancer Res. 2002, 22 (4), 2317–2319. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Howell, A.; DeFriend, D J.; Robertson, J F.; Blamey, R W.; Anderson, L.; Anderson, E.; Sutcliffe, F A.; Walton, P. Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. Br. J. Cancer 1996, 74 (2), 300–308. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Robertson, J F.R.; Harrison, M P. Equivalent single-dose pharmacokinetics of two different dosing methods of prolonged-release fulvestrant (‘Faslodex’) in post menopausal women with advanced breast cancer. Cancer Chemother. Pharmacol. 2003, 52 (4), 346–348. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Robertson, J F.; Erikstein, B.; Osborne, K C.; Pippen, J.; Come, S E.; Parker, L M.; Gertler, S.; Harrison, M P.; Clarke, D A. Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer. Clin. Pharmacokinet. 2004, 43 (8), 529–538. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Howell, A.; Robertson, J F.R.; Quaresma Albano, J.; Aschermannova, A.; Mauriac, L.; Kleeberg, U R.; Vergote, I.; Erikstein, B.; Webster, A.; Morris, C. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J. Clin. Oncol. 2002, 20 (16), 3396–3403. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Osborne, C K.; Pippen, J.; Jones, S E.; Parker, L M.; Ellis, M.; Come, S.; Gertler, S Z.; May, J T.; Burton, G.; Dimery, I.; Webster, A.; Morris, C.; Elledge, R.; Buzdar, A. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J. Clin. Oncol. 2002, 20 (16), 3386–3395. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Robertson, J F.; Osborne, C K.; Howell, A.; Jones, S E.; Mauriac, L.; Ellis, M.; Kleeberg, U R.; Come, S E.; Vergote, I.; Gertler, S.; Buzdar, A.; Webster, A.; Morris, C. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women—a prospective combined analysis of two multicenter trials. Cancer 2003, 98 (2), 229–238. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Pippen, J.; Osborne, C K.; Howell, A.; Robertson, J F.R. Fulvestrant (Faslodex®) versus anastrozole (Arimidex®) for the treatment of advanced breast cancer: a prospective combined survival analysis of two multicenter trials. Breast Cancer Res. Treat. 2003, 82 (Suppl. 1), S101. Abstract 426.
   Google Scholar
• Howell, A.; Robertson, J F.R.; Abram, P.; Lichinitser, M R.; Elledge, R.; Bajetta, E.; Watanabe, T.; Morris, C.; Webster, A.; Dimery, I.; Osborne, C K. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J. Clin. Oncol. 2004, 22 (9), 1605–1613. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Perey, L.; Thürlimann, B.; Hawle, H.; Bonnefoi, H.; Ahern, J.; Pagani, O.; Goldhirsch, A.; Dietrich, D. Fulvestrant (‘Faslodex’) as hormonal treatment in postmenopausal patients with advanced breast cancer progressing after treatment with tamoxifen and aromatase inhibitors. Breast Cancer Res. Treat. 2002, 76 (Suppl. 1), S72. Abstract 249.
   Google Scholar
• Steger, G.; Bartsch, R.; Wenzel, C.; Pluschnig, U.; Hussain, D.; Mader, R M.; Zielinski, C C. Fulvestrant (Faslodex®) in metastatic breast cancer. Breast Cancer Res. Treat. 2003, 82 (Suppl. 1), S104. Abstract 437.
   Google Scholar
• Franco, S.; Perez, A.; Tan-Chiu, E.; Frankel, C.; Vogel, C L. Fulvestrant (Faslodex®) demonstrates clinical benefit in heavily pretreated postmenopausal women with advanced breast cancer: a single-center experience. Breast Cancer Res. Treat. 2003, 82 (Suppl. 1), S105. Abstract 439.
   Google Scholar
• Petruzelka, L.; Zimovjanova, M.; Konopasek, B.; Mares, P.; Dlouha, Z. Fulvestrant in postmenopausal women with metastatic breast cancer progressing on prior endocrine therapy—updated results from an expanded access programme. Ann. Oncol. 2004, 13 (Suppl. 3), 136 pp.
   Google Scholar
• Howell, A. Postmenopausal women with advanced breast cancer who progress on fulvestrant or tamoxifen retain sensitivity to further endocrine therapies. Breast Cancer Res. Treat. 2002, 76 (Suppl. 1), S72. Abstract 251.
   Google Scholar
• Vergote, I.; Robertson, J F.R.; Kleeberg, U.; Burton, G.; Osborne, C K.; Mauriac, L. Postmenopausal women who progress on fulvestrant (‘Faslodex’) remain sensitive to further endocrine therapy. Breast Cancer Res. Treat. 2003, 79 (2), 207–211. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• McClelland, R A.; Barrow, D.; Madden, T A.; Dutkowski, C M.; Pamment, J.; Knowlden, J M.; Gee, J M.; Nicholson, R I. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 2001, 142 (7), 2776–2788. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar